A double-blind cross-over study on the effects of ORG OD14 compared to oestradiol valerate and placebo on lipid and carbohydrate metabolism in oophorectomized women

1983 ◽  
Vol 102 (3) ◽  
pp. 451-455 ◽  
Author(s):  
N. Crona ◽  
G Silfverstolpe ◽  
G. Samsioe
Keyword(s):  
Glucose Tolerance ◽  
Carbohydrate Metabolism ◽  
Glucose Tolerance Test ◽  
Marked Decrease ◽  
Clinical Stage ◽  
Density Lipoprotein ◽  
Tolerance Test ◽  
Continuous Treatment ◽  
Oral Glucose ◽  
Double Blind

Abstract. ORG OD14 is a synthetic steroid which in traditional bioassays has been shown to have oestrogenic and progestogenic as well as very weak androgenic-anabolic properties. As judged from earlier studies, this steroid seems suitable for continuous treatment of climacteric deficiency symptoms. The aim of this study was to evaluate the effects induced by OD14 on lipid, lipoprotein and carbohydrate metabolism, as compared to E2V and placebo. Twenty-two women, oophorectomized as part of the treatment of cervical carcinoma in clinical stage IB or IIA, were given ORG OD14 2.5 mg/day, oestradiol valerate (E2V) 2 mg/day and a placebo for 6 weeks each, in a double-blind cross-over study. There was a marked decrease in all lipid components of HDL (high density lipoprotein), i.e. total and free cholesterol, triglycerides and phospholipids (P < 0.001), after OD14. The oral glucose tolerance test showed higher values after OD14 compared to both E2V and placebo (P < 0.05), indicating a slightly impaired glucose tolerance. The lipid metabolic changes induced by OD14 indicate a rather strong androgenic influence in this respect.

KOHLENHYDRATSTOFFWECHSEL BEI HYPERTHYREOSE: EINFLUSS EINER THYREOSTATISCHEN THERAPIE AUF ORALE UND INTRAVENÖSE GLUCOSETOLERANZ UND INSULINAKTIVITÄT

1971 ◽  
Vol 67 (2) ◽  
pp. 277-287 ◽  
Author(s):  
E. Nieschlag ◽  
B. Wördehoff ◽  
H. J. Gilfrich ◽  
J. Michaelis ◽  
C. Overzier
Keyword(s):  
Glucose Tolerance ◽  
Carbohydrate Metabolism ◽  
Glucose Tolerance Test ◽  
Tolerance Test ◽  
Intravenous Glucose Tolerance Test ◽  
Oral Glucose ◽  
Oral Glucose Tolerance ◽  
Intravenous Glucose ◽  
Intravenous Glucose Tolerance ◽  
Initiation Of Therapy

ABSTRACT The influence of antithyroid therapy on the abnormalities of carbohydrate metabolism observed in hyperthyroidism was investigated in 10 patients. No history of diabetes mellitus was known in the patients or their families. 9 normal persons were taken as a control group. An oral and an intravenous glucose tolerance test were administered prior to and at intervals of 2 and 4 weeks after initiation of therapy. Prior to treatment an inpairment of oral glucose tolerance was observed, whereas the glucose assimilation coefficient in the intravenous glucose tolerance test was normal. Both tests however, revealed a significant rise in insulin values above normal. 2 weeks after initiation of therapy insulin values returned to normal during the intravenous glucose tolerance test. During the oral glucose tolerance test glucose and insulin concentration achieved normal levels only after 4 weeks of treatment. In all patients the abnormalities of carbohydrate metabolism observed were reversible.

scholarly journals Use of carnosine in the prevention of cardiometabolic risk factors in overweight and obese individuals: study protocol for a randomised, double-blind placebo-controlled trial

BMJ Open ◽  
2021 ◽  
Vol 11 (5) ◽  
pp. e043680
Author(s):  
Kirthi Menon ◽  
James D Cameron ◽  
Maximilian de Courten ◽  
Barbora de Courten
Keyword(s):  
Risk Factors ◽  
Cardiovascular Risk ◽  
Glucose Metabolism ◽  
Glucose Tolerance ◽  
Glucose Tolerance Test ◽  
Controlled Trial ◽  
Tolerance Test ◽  
Oral Glucose ◽  
Oral Glucose Tolerance ◽  
Double Blind

IntroductionCarnosine, an over the counter food supplement, has been shown to improve glucose metabolism as well as cardiovascular risk factors in animal and human studies through its anti-inflammatory, antioxidative, antiglycating and chelating properties. The aim of this study is to establish if carnosine supplementation improves obesity, insulin sensitivity, insulin secretion, cardiovascular risk factors including arterial stiffness and endothelial function, and other risk factors related to diabetes and cardiovascular disease in the overweight and obese population.Methods and analysisFifty participants will be recruited to be enrolled in a double-blind randomised controlled trial. Eligible participants with a body mass index (BMI) between 25 and 40 kg/m2 will be randomly assigned to the intervention or placebo group. Following a medical review and oral glucose tolerance test to check eligibility, participants will then undergo testing. At baseline, participants will have anthropometric measurements (BMI, dual X-ray absorptiometry and peripheral quantitative CT scan), measurements of glucose metabolism (oral glucose tolerance test, intravenous glucose tolerance test and euglycaemic hyperinsulinaemic clamp), cardiovascular measurements (central blood pressure, endothelial function and arterial stiffness), a muscle and fat biopsy, physical activity measurement, liver fibroscan, cognitive function and questionnaires to assess dietary habits, sleep quality, depression, and quality of life. Following baseline assessments, participants will be randomised to either 2 g carnosine or placebo for 15 weeks. In the 15th week, all assessments will be repeated. The preplanned outcome metric is the change between baseline and follow-up measures.Ethics and disseminationThis study is approved by the Human Research Ethics Committee of Monash Health and Monash University, Australia.Trial registration numberNCT02686996.

Abstract #873: Association of Patterns in the Oral Glucose Tolerance Test and Different Clinical Features in Patients with Insulinoma

2005 ◽  
Vol 11 ◽  
pp. 28
Author(s):  
Fanny Rodriguez Vallejo ◽  
Juan Manuel Rios Torres ◽  
Francisco J. Gomez-Pérez ◽  
Juan A. Rull Rodrigo ◽  
Bernardo Pérez Enriquez
Keyword(s):  
Glucose Tolerance ◽  
Oral Glucose Tolerance Test ◽  
Clinical Features ◽  
Glucose Tolerance Test ◽  
Tolerance Test ◽  
Oral Glucose ◽  
Oral Glucose Tolerance
Sign in / Sign up

Export Citation Format

Share Document